NeuroSigma, Inc., today announced positive preliminary findings from a clinical study using non-invasive external Trigeminal Nerve Stimulation with the Monarch eTNS System to treat combat veterans. Results were presented at the North American Neuromodulation Society (NANS) meeting in Las Vegas and mark the first report of using eTNS in patients with Traumatic Brain Injury (TBI). “Neuroimaging data indicate that 8 weeks of nightly eTNS treatment can produce a lasting desired influence on the activity of specific brain areas that are linked to TBI, along with improvements in memory, anxiety, and other symptoms that are common in patients with TBI,” said Ian A. Cook, M.D., NeuroSigma’s Chief Medical Officer. “TBI not only affects many of our combat veterans, but may also result from motor vehicle accidents and sports-related injuries.”
The Monarch eTNS System is composed of a cell-phone sized pulse generator and a single-use electric patch that is applied to the forehead. Signals are transmitted through lead wires to the patch in order to stimulate the trigeminal nerve in the skin of the forehead; triggering these nerve fibers sends signals to targeted brain regions and changes the activity there. The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain, bilaterally and at high frequency. The trigeminal nerve projects directly or indirectly to specific areas of the brain which are involved in epilepsy, depression, attention-deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and other disorders.